All Updates

All Updates

icon
Filter
Product updates
Guardant Health launches enhanced Guardant360 TissueNext test with up to 500 biomarkers for cancer detection
Precision Medicine
Jun 4, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Product updates
Regulation/policy
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
Precision Medicine

Precision Medicine

Jun 4, 2024

Guardant Health launches enhanced Guardant360 TissueNext test with up to 500 biomarkers for cancer detection

Product updates

  • Guardant Health has introduced a new version of its Guardant360 TissueNext test, identifying 498 genes in tumor tissue samples. The test will be offered to Medicare fee-for-service patients with advanced solid tumor cancers.

  • Key features of the product include expanded gene coverage of close to 500 biomarkers, compatibility with Guardant’s other genomic profiling tests, and operational workflow improvements for quicker results. 

  • The company claims that the test can help oncologists make more informed decisions about treatment strategies and potentially boost patient outcomes by identifying a broader range of actionable biomarkers in tumor tissue.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.